Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme, Isis Retool Mipomersen Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms confident, but some analysts skeptical about what might be required for approval of lipid antisense drug.

You may also be interested in...



Genzyme/Isis Expand Clinical Trial Program For Mipomersen

Design for cholesterol-lowering candidate’s outcomes study, to start in 2010, depends on data from four additional clinical trials.

Genzyme/Isis Expand Clinical Trial Program For Mipomersen

Design for cholesterol-lowering candidate’s outcomes study, to start in 2010, depends on data from four additional clinical trials.

2008 Deals Of The Year

Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS067970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel